Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$54.90M
EBITDA Margin
-40.55%
TTM Avg
-30.41%
3Y Avg
-34.23%
5Y Avg
-32.87%
Market Cap
$53.63M
EBITDA Margin
-5927.25%
TTM Avg
-3470.39%
3Y Avg
-2050.54%
5Y Avg
-1465.25%
Market Cap
$56.43M
EBITDA Margin
-89640.62%
TTM Avg
-44862.17%
3Y Avg
-44862.17%
5Y Avg
-44862.17%
Market Cap
$51.78M
EBITDA Margin
-108.45%
TTM Avg
-10676.44%
3Y Avg
-10454.97%
5Y Avg
-429870.64%
Market Cap
$51.33M
EBITDA Margin
-9115.35%
TTM Avg
-8798.34%
3Y Avg
-6751.54%
5Y Avg
-5839.94%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Dogwood Therapeutics, Inc. (DWTX) | $53.15M | N/A | N/A | N/A | N/A |
| Spectral AI, Inc. (MDAI)vs › | $54.90M | -40.55% | -30.41% | -34.23% | -32.87% |
| ImageneBio Inc (IMA)vs › | $53.63M | -5927.25% | -3470.39% | -2050.54% | -1465.25% |
| biote Corp. (BTMD)vs › | $50.28M | 20.40% | 19.12% | 4.66% | 12.12% |
| Connect Biopharma Holdings Limited (CNTB)vs › | $56.43M | -89640.62% | -44862.17% | -44862.17% | -44862.17% |
| Aldeyra The (ALDX)vs › | $56.71M | N/A | N/A | N/A | N/A |
| Apollomics, Inc. (APLM)vs › | $51.78M | -108.45% | -10676.44% | -10454.97% | -429870.64% |
| Envoy Medical, Inc. (COCH)vs › | $51.33M | -9115.35% | -8798.34% | -6751.54% | -5839.94% |
| eXoZymes, Inc. (EXOZ)vs › | $52.31M | N/A | N/A | N/A | N/A |
| NOMAD Power Solutions, Inc. (NMAD)vs › | $50.86M | N/A | N/A | N/A | N/A |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
